📊 VNRX Key Takeaways
Is Volitionrx Ltd. (VNRX) a Good Investment?
VNRX exhibits severe financial distress with negative stockholders' equity (-$32M), critical liquidity crisis (0.33x current ratio), and negative operating cash flows of -$5.3M annually against only $3.1M in cash reserves—indicating months of runway before potential insolvency. While 40% revenue growth suggests market traction in diagnostics, it is insufficient to offset the company's structural unprofitability, accumulated losses, and inability to fund operations without immediate dilutive financing or strategic intervention.
Why Buy Volitionrx Ltd. Stock? VNRX Key Strengths
- 40% year-over-year revenue growth demonstrates emerging market demand for diagnostic products
- Marginal improvement in net income trend (0.6% YoY) shows some progress toward reducing losses
- Positioned in in-vitro diagnostic sector with significant long-term market potential
VNRX Stock Risks: Volitionrx Ltd. Investment Risks
- Negative stockholders' equity of -$32M indicates technical insolvency; liabilities exceed assets by $32M
- Critical liquidity crisis: current ratio of 0.33x means company cannot cover current liabilities; cash runway approximately 6-8 months at current burn rate
- Operating cash outflows of -$5.3M annually against minimal $3.1M cash reserves create imminent solvency risk without capital raise or drastic operational restructuring
- Negative operating margin of -543% and net margin of -676.6% demonstrate unsustainable unit economics with no clear path to profitability
Key Metrics to Watch
- Monthly cash burn rate and days of cash remaining (survival metric)
- Revenue growth sustainability and ability to achieve gross margin expansion
- Debt restructuring announcements or capital raise (dilution risk) and use of proceeds
Volitionrx Ltd. (VNRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
VNRX Profit Margin, ROE & Profitability Analysis
VNRX vs Healthcare Sector: How Volitionrx Ltd. Compares
How Volitionrx Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Volitionrx Ltd. Stock Overvalued? VNRX Valuation Analysis 2026
Based on fundamental analysis, Volitionrx Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Volitionrx Ltd. Balance Sheet: VNRX Debt, Cash & Liquidity
VNRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Volitionrx Ltd.'s revenue has grown significantly by 1,819% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.50 indicates the company is currently unprofitable.
VNRX Revenue Growth, EPS Growth & YoY Performance
VNRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $246.4K | -$5.4M | $-0.97 |
| Q3 2025 | $474.5K | -$5.4M | $-0.05 |
| Q2 2025 | $395.8K | -$6.3M | $-0.06 |
| Q1 2025 | $171.5K | -$5.4M | $-0.06 |
| Q3 2024 | $165.2K | -$5.9M | N/A |
| Q2 2024 | $216.3K | -$7.1M | N/A |
| Q1 2024 | $149.8K | -$8.5M | N/A |
| Q3 2023 | $32.7K | -$7.7M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Volitionrx Ltd. Dividends, Buybacks & Capital Allocation
VNRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Volitionrx Ltd. (CIK: 0000093314)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VNRX
What is the AI rating for VNRX?
Volitionrx Ltd. (VNRX) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VNRX's key strengths?
Claude: 40% year-over-year revenue growth demonstrates emerging market demand for diagnostic products. Marginal improvement in net income trend (0.6% YoY) shows some progress toward reducing losses.
What are the risks of investing in VNRX?
Claude: Negative stockholders' equity of -$32M indicates technical insolvency; liabilities exceed assets by $32M. Critical liquidity crisis: current ratio of 0.33x means company cannot cover current liabilities; cash runway approximately 6-8 months at current burn rate.
What is VNRX's revenue and growth?
Volitionrx Ltd. reported revenue of $985.1K.
Does VNRX pay dividends?
Volitionrx Ltd. does not currently pay dividends.
Where can I find VNRX SEC filings?
Official SEC filings for Volitionrx Ltd. (CIK: 0000093314) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VNRX's EPS?
Volitionrx Ltd. has a diluted EPS of $-0.97.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VNRX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Volitionrx Ltd. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VNRX stock overvalued or undervalued?
Valuation metrics for VNRX: ROE of N/A (sector avg: 15%), net margin of -676.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VNRX stock in 2026?
Our dual AI analysis gives Volitionrx Ltd. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VNRX's free cash flow?
Volitionrx Ltd.'s operating cash flow is $-5.3M, with capital expenditures of $9.2K. FCF margin is -536.9%.
How does VNRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -676.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.33 (avg: 2).